Raymond Debbane - 13 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
Director
Signature
/s/ Raymond Debbane
Issuer symbol
LXRX
Transactions as of
13 Feb 2026
Net transactions value
+$352,889
Form type
4
Filing time
18 Feb 2026, 16:30:52 UTC
Previous filing
03 Jun 2025
Next filing
23 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DEBBANE RAYMOND Director 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS /s/ Raymond Debbane 18 Feb 2026 0001053890

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Purchase $75,877 +57,952 +4.2% $1.31 1,443,641 13 Feb 2026 Direct F1
transaction LXRX Common Stock Purchase $100,544 +76,857 +5.3% $1.31 1,520,498 17 Feb 2026 Direct F2
transaction LXRX Common Stock Purchase $176,468 +133,688 +8.8% $1.32 1,654,186 18 Feb 2026 Direct F3
holding LXRX Common Stock 1,538,462 13 Feb 2026 By Avicenna Life Sci Master Fund LP and related parties
holding LXRX Common Stock 7,362,368 13 Feb 2026 By Invus Public Equities, L.P. and related parties
holding LXRX Common Stock 5,451,204 13 Feb 2026 By Invus US Partners, LLC and related parties
holding LXRX Common Stock 35,402,689 13 Feb 2026 By Invus, L.P. and related parties
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.31 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.
F2 Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.295 to $1.31 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.
F3 Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.315 to $1.32 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.